Ligand Pharmaceuticals Incorporated (LGND)
| Market Cap | 4.27B +103.3% |
| Revenue (ttm) | 274.48M +51.2% |
| Net Income | 153.56M |
| EPS | 7.50 |
| Shares Out | 20.04M |
| PE Ratio | 28.43 |
| Forward PE | 40.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127,863 |
| Open | 216.66 |
| Previous Close | 218.98 |
| Day's Range | 212.70 - 218.13 |
| 52-Week Range | 98.89 - 247.38 |
| Beta | 1.07 |
| Analysts | Strong Buy |
| Price Target | 271.80 (+20.87%) |
| Earnings Date | May 7, 2026 |
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteopor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price target is $271.8, which is an increase of 20.87% from the latest price.
News
Ligand reports Q1 adjusted EPS $1.63, consensus $1.80
Reports Q1 revenue $51.72M, consensus $58.86M. “The first few months of 2026 have already proven to be highly productive and transformative for Ligand (LGND),” said Todd Davis, CEO of Ligand.
Ligand backs FY26 adjusted EPS view $8.50-$9.50, consensus $9.21
Backs FY26 revenue view $270M-$310M, consensus $288.97M. The company said, “Ligand (LGND) is reaffirming its 2026 full-year financial guidance, which was raised on April 27, 2026 in connection with th...
Ligand Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 56% royalty revenue and 23% adjusted EPS growth year-over-year, driven by portfolio expansion and the strategic shift to royalty aggregation. The XOMA Royalty acquisition is expected to be immediately accretive, further diversifying assets and accelerating long-term growth.
Ligand Reports First Quarter 2026 Financial Results
First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution ...
Orchestra BioMed receives $15M payment from Ligand
Orchestra BioMed (OBIO) announced the receipt of a $15M payment from Ligand (LGND) pursuant to the previously disclosed revenue participation right purchase and sale agreement. The payment completes a...
Ligand to Participate in May Investor Conferences
JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c...
Ligand price target raised to $289 from $243 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Ligand (LGND) to $289 from $243 and keeps a Buy rating on the shares. The firm cites the company’s…
Ligand price target raised to $252 from $235 at RBC Capital
RBC Capital raised the firm’s price target on Ligand (LGND) to $252 from $235 and keeps an Outperform rating on the shares. The company’s acquisition of Xoma is a strong…
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the propo...
Ligand price target raised to $255 from $230 at Stifel
Stifel raised the firm’s price target on Ligand (LGND) to $255 from $230 and keeps a Buy rating on the shares after the company agreed to acquire Xoma (XOMA) for…
Ligand price target raised to $260 from $250 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Ligand (LGND) to $260 from $250 and keeps a Buy rating on the shares after the company announced plans to…
Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million
Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the companies said on Monday.
Ligand Pharmaceuticals Transcript: M&A announcement
The acquisition of XOMA Royalty will double the portfolio size, add seven commercial royalties, and over 100 development-stage programs, driving immediate and long-term earnings growth. The all-cash deal is expected to be accretive from 2026, with significant synergies and no shareholder dilution.
Ligand to acquire Xoma for $39.00 per share in cash
Ligand (LGND) and Xoma (XOMA) announced that the companies have entered into a definitive agreement under which Ligand will acquire Xoma Royalty for $39.00 per share of common stock in…
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary por...
Ligand to buy Xoma for $39 per share, WSJ reports
Ligand Pharmaceuticals (LGND) has reached a roughly $740M deal to buy Xoma XOMA Royalty (XOMA) at $39 per share, people familiar with the matter told The Wall Street Journal. The…
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million
Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their sales if the drugs succeed.
Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program
PARIS, France – 22 April 2026: Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces it will deli...
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026.
Ligand price target raised to $282 from $276 at Citi
Citi raised the firm’s price target on Ligand (LGND) to $282 from $276 and keeps a Buy rating on the shares after the company’s partner Travere received FDA approval of…
Ligand price target raised to $250 from $244 at BofA
BofA raised the firm’s price target on Ligand (LGND) to $250 from $244 and keeps a Buy rating on the shares after Travere Therapeutics (TVTX) announced FDA approved Filspari’s sNDA…
Ligand partner Travere Therapeutics announces FDA approval for Filspari
Ligand (LGND) announced that its partner Travere Therapeutics (TVTX) has received approval from the FDA for Filspari to reduce proteinuria in adult and pediatric patients aged eight years and older…
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., ...
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown...
Citi ups Ligand target, opens ‘upside 90-day catalyst watch’
Citi raised the firm’s price target on Ligand (LGND) to $276 from $270 and keeps a Buy rating on the shares. Citi also added an “upside 90-day catalyst watch” on…